Experimental Agents for the Treatment of Atherosclerosis: New Directions
Open Access
- 1 February 2021
- journal article
- review article
- Published by Taylor & Francis Ltd in Journal of Experimental Pharmacology
- Vol. ume 13, 161-179
- https://doi.org/10.2147/jep.s265642
Abstract
Abstract: Cardiovascular and related metabolic disorders constitute a worldwide health challenge. Atherosclerosis is a chronic inflammatory condition based on both dyslipidemia and inflammation. Therefore, even when dyslipidemia is controlled, the risk of atherosclerosis remains. Among the most efficient inflammatory mediators used as therapeutic tools in cardiovascular disease are the interleukins, which are pro-inflammatory mediators like cytokines. Moreover, a protein kinase inhibitors, p38 mitogen-activated protein kinase (MAPK) inhibitor, and an inhibitor of a leukocyte adhesion molecule, P-Selectin, have also presented therapeutic potential for this disorder. Colchicine, being an inexpensive therapeutic option, has been proved to be suitable for the prevention of atherosclerosis. In this review, we summarize all the studies, from 2010 to 2020, in which treatment approaches based on the agents mentioned above are evaluated in the management of atherosclerosis.Keywords
This publication has 51 references indexed in Scilit:
- Transsignaling of Interleukin-6 Crucially Contributes to Atherosclerosis in MiceArteriosclerosis, Thrombosis, and Vascular Biology, 2012
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesBlood, 2011
- The immune system in atherosclerosisNature Immunology, 2011
- Many cytokines are very useful therapeutic targets in diseaseJCI Insight, 2008
- Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in MiceCirculation, 2006
- The immune response in atherosclerosis: a double-edged swordNature Reviews Immunology, 2006
- INFLAMMATION AND ATHEROSCLEROSISAnnual review of pathology, 2006
- Autoimmune and Inflammatory Mechanisms in AtherosclerosisAnnual Review of Immunology, 2004
- Atherosclerosis: The Road AheadCell, 2001
- Reduction of atherosclerosis in mice by inhibition of CD40 signallingNature, 1998